Nippon India MNC Fund

Direct · Growth

AI Summary

Performance

Nippon India MNC Fund has significantly underperformed its category, with a 1Y SIP XIRR of just 2.88% versus the thematic category average of 11.61%. The 1Y rolling return mean of 4.01% confirms weak lump-sum performance as well, and calendar year 2026 shows a -10.8% decline after a positive 10.25% in 2025. This suggests the MNC theme is currently out of favor relative to broader thematic peers.

Risk

The fund shows a modest maximum drawdown of -0.15% over 74 days with only 2 drawdown events exceeding 10%, indicating contained recent volatility. However, the Calmar Ratio of 0.2364 reflects weak risk-adjusted returns, as the low drawdown has not been paired with meaningful returns. The negative 2026 calendar return of -10.8% indicates the fund is not immune to meaningful downside during weak market phases.

Portfolio

The portfolio is spread across 36 stocks with the top 10 accounting for roughly 52.6% of NAV, led by Cummins India (7.14%), Nestle India (6.86%), and Britannia (6.57%). Sector exposure is reasonably diversified, with Food Products (13.4%), Automobiles (11.7%), and Pharma (10.5%) as the largest allocations. The mix skews toward consumer-facing and industrial MNC franchises, providing quality bias but limited exposure to high-growth technology beyond 7.6% in IT-Software.

Category Positioning

The fund trails its category meaningfully on the primary SIP XIRR metric, with a 1Y return of 2.88% against a category average of 11.61%. While longer-term category averages (3Y to 10Y SIP XIRR of 16.36% to 17.5%) suggest the theme has historically rewarded patient investors, the fund's current 1Y figures indicate it is in a pronounced underperformance phase. Investors should treat this as a cyclical laggard rather than a consistent category leader based on available data.

Investor Suitability

This fund suits investors with a high risk tolerance and a long time horizon of 5-7 years or more, given the thematic nature and current underperformance cycle. It is appropriate as a satellite allocation (typically 5-10% of an equity portfolio) for those who believe in the long-term pricing power of multinational companies operating in India. Investors seeking near-term returns or core portfolio exposure should be cautious given the weak 1Y XIRR of 2.88% and negative 2026 calendar return.

  • Diversified 36-stock portfolio with a quality MNC bias, anchored by established names like Nestle India, Britannia, and Hindustan Unilever
  • Contained recent drawdown profile with a maximum drawdown of only -0.15% and just 2 drawdown events exceeding 10%
  • Reasonable expense ratio of 1.17% for a thematic fund in the Direct plan

  • Severe 1Y underperformance versus category, with SIP XIRR of 2.88% against a category average of 11.61%
  • Weak risk-adjusted returns as reflected in a Calmar Ratio of only 0.2364, alongside a -10.8% calendar year return in 2026

Generated on 28-10-2026, 2:18 AM. Verify before investing.

₹9.88
30 Oct 2026
NAV
3.0%
Weighted CAGR
?
-0.46
Sharpe
-15.0%
Max Drawdown
?
1.17%
TER

If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.

Duration Invested Median Value XIRR Min XIRR Max XIRR
1 Year ₹12.00 L ₹12.26 L 2.5% -17.4% 14.8%

SIP returns vs benchmark & category

Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.

Duration Fund SIP XIRR Category avg
1 Year 2.5% 11.6%

Duration Mean Median Min Max Sharpe Sortino % Positive Cat. Mean Cat. Median
1 Year 3.0% 2.1% -10.3% 15.4% -0.46 -0.46 53% — —

-15.0%
Max Drawdown
2 mo
Drawdown Duration
Not recovered
Recovery Time
-3.3%
Avg Drawdown

Calmar Ratio by Duration

0.20
1Y

36
Total Holdings
52.6%
Top 10 Weight
21
Sectors
# Stock % of NAV
1 Cummins India Limited 7.14%
2 Nestle India Limited 6.86%
3 Britannia Industries Limited 6.57%
4 Hyundai Motor India Ltd 6.08%
5 Maruti Suzuki India Limited 5.61%
6 Hindustan Unilever Limited 4.92%
7 Kansai Nerolac Paints Limited 3.98%
8 Samvardhana Motherson International Limited 3.87%
9 Sai Life Sciences Limited 3.80%
10 Fortis Healthcare Limited 3.75%